HBOT Conversations:
Laurie Anderson (Part 3)
Healing COVID with HBOT
Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF). Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center. For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.
Watch the Podcast
We continue Dr. Laurie Anderson’s HBOT News Network interview, diving in deeper to discuss our veteran population, does HBOT have a therapeutic index, and what is the research telling us about the HBOT industry.
Her interview has been released as a three part series. Part 1 and Part 2 has already been released with both focusing on her HBOT journey with COVID & Lyme Disease.
In Part 3 of Laurie’s podcast the conversation shifts. It starts with the medical industry and the unfortunate “bad rap” that Hyperbaric Oxygen sometimes receives. Dr, Laurie refers to HBOT as a gift, so it’s truly unfortunate when the media focuses on the negative instead of the positive, influencing the public to not even try this life saving therapy. Research trials are discussed, including the problems that the hyperbaric industry has identified in the sham, placebo and/or control group when researchers try to mimic HBOT with little pressure and they discover that everyone starts to improve. Those of us in this industry understand and effortlessly work to enlighten others that any amount of pressure is good and therapeutic.
The topic of our US military and the high rate of suicide among our service man and women arises. Is there a solution to the veteran suicide epidemic our country is facing? It appears there is. di Girolamo speaks of Patriot Hyperbarics in Tulsa, and the success they have had treating veterans with Hyperbaric Oxygen Therapy.
“The Patriot Clinics in Tulsa treated some 500 veterans with PTSD, with donated money, donated chambers, and healed them. Most of them war-fighters, were in a bedroom, locked in the dark for years and years, like seven, ten years. And then they found Patriot Clinics and they got 40 treatments and then they got their executive function back. Some of them starting businesses. I saw videos of guys, you know, in the car on their way to the clinic on the first day and then on the 40th day, talking about their experience, it was just amazing.
There wasn’t some combined study about that. 500 souls were saved that didn’t commit suicide, they worked their way out of it.”
Dr. Laurie, who is a Doctor of Pharmacy, brings up an excellent point, and one that we’ve never discussed before on HBOT News. We know that the FDA ultimately states that oxygen is a drug, and you are required to have a prescription for it. But does Hyperbaric Oxygen have a therapeutic index like other drugs? And if so… how would a patient know they have reached the therapeutic index and how long is a patient at the therapeutic index? She explains it like this…
“If I apply this to drugs, like with a drug we would want to keep the level, generally, we try to keep the level of a drug in the blood inside the therapeutic index, right? So sometimes, depending on the half life of the drug, you can be in your therapeutic index by taking it once a day so you trickle up and down in between that therapeutic index. Some drugs have a shorter half life and you have to take it twice a day to stay in that therapeutic index.
So what keeps you in whatever is the defined therapeutic index, if that can be translated to oxygen therapy, you know, is it daily? Is it twice a day?”
di Girolamo wonders if in 20 years from now the industry will look back on this conversation and be shocked that we weren’t more focused on the therapeutic index. He stresses that the hyperbaric industry can’t even come together and decide the specific definition of hyperbaric oxygen, much less all these variables that Dr. Laurie has opened our eyes to.
Dr. Laurie ends her time here with HBOT News stressing that for her HBOT healed her during a very sick time with COVID, and it helped her with many of the Lyme Disease symptoms she struggled with for years. It worked for her, and she said it’s definitely worth a try to see if it can work for you.
Guests
Dr. Laurie Anderson, Pharm.D.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.
When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.
Subscribe Now, It’s Free!
Recent HBOT News
Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.
Abstract: Despite successful surgery, 30-50% of patients with resectable non-small cell lung cancer develop tumor recurrence within 5 years of surgery. In this prospective study, we performed CTC enumerations in 40 patients with non-metastatic lung adenocarcinoma...
Clinical Trial – Fixed Dose Spinal Bupivacaine for Cesarean Delivery
The study is designed to compare the effectiveness of spinal anesthesia performed with fixed
dose of hyperbaric bupivacaine regardless of patient’s height and weight and anesthesia with
the dose of bupivacaine that is adjusted to their height. Our clinical experience shows that
spinal anesthesia using specific, relatively high dose of hyperbaric bupivacaine combined
with opioid is very effective, regardless of parturient’s weight and height, provides very
good surgical conditions and assures patient’s comfort while the rate of anesthesia – related
complications is similar or less. Therefore, using height-adjusted protocols, although
preferred in some centres, might not be necessary in order to provide good anaesthesia for
cesarean delivery. Fixed dose regimen may have some additional advantages in obstetric
anesthesia settings, as many of cesareans are performed out of hours, giving less room for
mistakes in less experienced hands.
Two groups of parturients undergoing cesarean section are to be compared: anesthetized with
fixed-dose regimen (intervention group) and anesthetized with height-adjusted dose regimen
(control group). Patients are going to be randomized to one of the above groups, two
anesthetists will be involved in anesthetic procedure: anesthetist that looks after the
patient throughout the procedure will be blinded to the dose of anesthetic given
intrathecally. Therefore his judgment of anesthetic effectiveness is not going to be biased
and all patients will receive the same perioperative care in terms of fluid therapy,
management of possible anesthesia – related complications and postoperative pain control.
Rate of effective spinal anesthetics, defined as adequate block level and no need for
additional intraoperative analgesia has been established as primary outcome measure.
Secondary outcome measures are rate of complications and amount of opioids used
postoperatively. These are going to be statistically compared.
Clinical Trial – a Small Dose of Naloxone,Minimize Intrathecal Morphine Side Effects
I.V naloxone decreases incidence and severity of the common morphine side effects (pruritis,
nausea/emesis, constipation, urinary retention, respiratory depression and undesirable
sedation) so using it as additive to intrathecal morphine in patients undergoing anal
surgeries under spinal anesthesia may be beneficail